Need Writing Help 11/4/2023

Law101
HSE420Module3Chapter4Slides.pptx

Biosecurity & Bioterrorism: Containing and Preventing Biological Threats

Chapter 4

Category B Diseases and Agents

Learning Objectives

Key Terminology

HHS Category B - Criteria

Moderately easy to disseminate

Result in moderate morbidity rates and low mortality rates

Require specific enhancements for diagnostic capacity and disease surveillance

Category B Agents and Diseases

Disease Agent Type of Agent Zoonoses Contagious Person-to-Person
Brucellosis Brucella species Bacteria Yes No
Glanders Burkholderia mallei Bacteria Yes No
Melioidosis Burkholderia pseudomallei Bacteria Yes No
Q Fever Coxiella burnetii Rickettsia Yes No
Psittacosis Chlamydophila psittacii Bacteria Yes No
Food and Water Safety Threats* Salmonella species; Shigella dysenteriae Type 1; Escherichia coli O157:H7; Vibrio cholerae; Typhi Bacteria No No
Viral Encephalitis Several Arboviruses (e.g., VEE, WEE, EEE, SLE) Virus Yes No
Epsilon Toxin Poisoning* Clostridium perfringens Epsilon Toxin Bacteria-derived toxin No No
SEB Poisoning* Staphylococcal Enterotoxin B (SEB) Bacteria-derived toxin No No
Ricin Poisoning Ricin toxin from Ricinus communis Plant-derived toxin No No

Brucellosis

Malta fever

Undulant Fever

Bang’s Disease

Image courtesy of CDC PHIL

Brucella spp.

Gram negative, coccobacilli bacteria

Facultative, intracellular organism

Environmental persistence

Temp, pH, humidity

Frozen and aborted materials

Multiple species

Image courtesy of CDC PHIL

7

Malta Fever

450 BC: Described by Hippocrates

1905: Introduction into the U.S.

1914: B. suis Indiana, United States

1953: B. ovis New Zealand, Australia

1966: B. canis in dogs, caribou and reindeer

8

History

Alice Evans, American bacteriologist

Credited with linking the organisms

Similar morphology and pathology between:

Bang’s Bacterium abortus

Bruce’s Micrococcus melitensis

Nomenclature today credited to Sir David Bruce

Brucella abortus and Brucella melitensis

9

Brucella species summary

Species Biovar/Serovar Natural Host Human Pathogen
B. abortus 1-6, 9 cattle yes
B.melitensis 1-3 goats, sheep yes
B. suis 1, 3 swine yes
2 hares yes
4 reindeer, caribou yes
5 rodents yes
B. canis none dogs, other canids yes
B. ovis none sheep no
B. neotomae none Desert wood rat no
B. maris marine mammals unknown

10

Brucella melitensis

Latin America, Middle East, Mediterranean, eastern Europe, Asia, and parts of Africa

Accounts for most human cases

In the Mediterranean and Middle East

Up to 78 cases/100,000 people/year

Arabic Peninsula 20% seroprevalence

Recent emergence in cattle on Middle Eastern intensive dairy farms

11

Brucella abortus

Worldwide

Some countries have eradicated

Notifiable disease in many countries

Poor surveillance and reporting due to lack of recognition

Fever of Unknown Origin (FUO)

12

Brucella suis

Biovars 1 and 3

Worldwide problems where swine are raised

Free

United Kingdom, Canada

Eradicated

Holland, Denmark

Low Incidence

Middle East, North Africa

13

Transmission to Humans

Conjunctiva or broken skin contacting infected tissues

Blood, urine, vaginal discharges, aborted fetuses, placentas

Ingestion

Raw milk & unpasteurized dairy products

Rarely through undercooked meat

14

Transmission to Humans

Inhalation of infectious aerosols

Pens, stables, slaughter houses

Inoculation with vaccines

B. abortus strain 19, RB-51

B. melitensis Rev-1

Conjunctival splashes, injection

Person-to-person transmission is very rare

Incubation varies

7-21 days to several months

15

Transmission in Animals

Ingestion of infected tissues or body fluids

Contact with infected tissues or body fluids

Mucous membranes, injections

Venereal

Swine, sheep, goats, dogs

16

Who is at Risk Normally?

Occupational Disease

Cattle ranchers/ dairy farmers

Veterinarians

Abattoir workers

Meat inspectors

Lab workers

Hunters

Travelers

17

Brucellosis

United States

Approximately 100 cases per year

Less than 0.5 cases/100,000 people

Mostly California, Florida, Texas, Virginia

Many cases associated with consumption of foreign cheeses

18

Image courtesy of CDC

Human Disease

Can affect any organ or organ system

All patients have a cyclical fever

Variability in clinical signs

Headache, weakness, arthralgia, depression, weight loss, fatigue, liver dysfunction

20

Human Disease

20-60% of cases

Osteoarticular complications

Arthritis, spondylitis, osteomyelitis

Hepatomegaly may occur

Gastrointestinal complications

2-20% of cases

Genitourinary involvement

Orchitis and epididymitis most common

21

Human Disease

Neurological

Depression, mental fatigue

Cardiovascular

Endocarditis resulting in death

Chronic brucellosis is hard to define

Length, type and response to treatment variable

Localized infection

Blood donations of infected should not be accepted

22

Diagnosis in Humans

Isolation of organism

Blood, bone marrow, other tissues

Serum agglutination test

Fourfold or greater rise in titer

Samples 2 weeks apart

Immunofluorescence of organism in clinical specimen

PCR

23

Treatment of Choice

Combination therapy has the best efficacy

Doxycycline for six weeks in combination with streptomycin for 2-3 weeks or rifampin for 6 weeks

CNS cases treat 6-9 months

Same for endocarditis cases plus surgical replacement of valves

24

Brucella as a Bioweapon

Aerosolized B. melitensis

City of 100,000 people

Inhale 1,000 cells (2% decay per min)

Case-fatality rate of 0.5%

50% hospitalized for 7 days

Outpatients required 14 visits

5% relapsed

Results

82,500 cases requiring extended therapy

413 deaths

$477.7 million in economic impact

25

Glanders & Melioidosis

Image courtesy of USDA ARS

26

Burkholderia

Burkholderia mallei

Gram negative bacillus

Exists primarily in infected host

Withstands drying for 2-3 weeks

Killed by sunlight and high temp

Related to Burkholderia pseudomallei

Cause of meliodiosis

Image courtesy of CDC PHIL

27

History

3rd Century BC

Described by Aristotle

1664: Contagious nature recognized

1830: Zoonotic nature suspected

1891: Mallein test developed

1900: Control programs implemented

28

History

World War I

Suspected use as biological

agent to infect Russian horses

and mules

Affected troops and supply convoys

Large number of human cases

in Russia during and after WWI

29

History

World War II

Japanese infected horses, civilians

and POW’s

U.S. and Russia investigated

use as biological weapon

30

History

1934

Eliminated from animals in U.S.

1945

Six laboratory-acquired cases at Camp Detrick

2000

Human case in laboratory worker at USAMRIID

31

Transmission: Humans

Direct contact with infected animals

Abraded skin

Mucous membranes

Inhalation

Person-to-person (rare)

Ingestion has never been recorded in humans

32

Glanders is transmitted to humans by direct contact with infected animals. The bacteria enter the body through abraded or lacerated skin and through mucosal surfaces of the eyes, nose and mouth. The bacteria can also be acquired through inhalation of infectious material. Cases of human-to-human transmission have also been reported. No known cases of human intestinal glanders are recorded.

Transmission: Animals

Ingestion: Major route

Inhalation: Less likely

Direct contact: Minor route

Enhanced by shared food and water facilities

33

Epidemiology

Endemic

Parts of Africa, the Middle East, and Asia

Sporadic cases

South and Central America

Possible occurrence

Balkan states and former Soviet republics

Once widespread, has been eradicated in many countries

No longer endemic to North America

34

Host Range

Affects solipeds

Donkeys and mules

Acute form

Horses

Chronic form

Carnivores, humans and goats susceptible

Swine and cattle resistant

35

Who Is At Risk Normally?

Veterinarians

Groomers

Horsemen

Butchers

Lab workers

36

Disease in Humans

Four forms of infection

Localized cutaneous

Pulmonary

Septicemia

Chronic form

Generalized symptoms

Fever, malaise, muscle aches, chest pain

Case-fatality rate: 95% (untreated)

37

Clinical Signs: Cutaneous

Incubation period: 1-5 days

Erythema and ulceration of skin

Lymphadenopathy

Nodules

Along lymph vessels

Highly infectious exudate

Case fatality rate: 20% treated

38

Clinical Signs: Pulmonary

Incubation period: 10-14 days

Inhalation of aerosolized bacteria

Hematogenous spread to lungs

Pneumonia, pulmonary abscesses, pleural effusion

39

Clinical Signs: Septicemia

Incubation period: 7-10 days

Any site of infection can lead to sepsis

Fever, chills, myalgia, chest pain, rash

Tachycardia, jaundice, photophobia, lacrimation

Case-fatality rate: 60% treated

Rapidly fatal

40

Clinical Signs: Chronic

Glanders - “Farcy”

Multiple abscesses

Muscles, joints, spleen, liver

Case-fatality rate: 60% (treated)

Relapses common

41

Glanders - Differential Diagnosis

Typhoid fever

Tuberculosis

Syphilis

Erysipelas

Lymphangitis

Pyemia

Yaws

Melioidosis

42

Diagnosis: Humans

Culture and gram stain

Sputum, urine, skin lesions, blood

Gram negative bacilli

Safety pin appearance

Agglutination tests

May be positive after 7-10 days

High background titer in normal sera makes interpretation difficult

43

Diagnosis: Humans

Complement fixation

More specific

Positive if titer is equal to or greater than 1:20

Chest radiograph

44

Treatment

Limited information on treatment

Long term antibiotic treatment necessary (1-12 months)

No proven pre- or post-exposure prophylaxis

No vaccine

45

Prevention: Humans

Elimination of disease in animals

Biosafety level 3 required in labs

Protective clothing during exams and necropsy

Gloves and mask

46

Prevention

Horses

Early detection and quarantine with disinfection

Reportable to state veterinarian

Vaccine not available for humans or animals

47

Glanders as a Biological Weapon

History

Very few organisms required to cause disease

Easily produced

Pulmonary form has high mortality

Limited experience with disease can slow diagnosis and treatment

48

Q Fever

Query Fever

Coxiellosis

Image courtesy of USDA ARS

49

Coxiella burnetii

Rickettsial agent

Obligate intracellular parasite

Stable and resistant

Killed by pasteurization

Two antigenic phases

Phase 1: virulent

Phase 2: less pathogenic

Spore forming

50

History

1935

1st described in Queensland, Australia

Found in ticks in Montana

Outbreaks

Among military troops

When present in areas with infected animals

Cities and towns

Downwind from farms

By roads traveled by animals

51

Transmission

Aerosol

Parturient fluids

109 bacteria per gram of placenta

Urine, feces, milk

Wind-borne

Direct contact

Fomites

Ingestion

Arthropods (ticks)

52

Transmission

Person-to-person (rare)

Transplacental (congenital)

Blood transfusions

Bone marrow transplants

Intradermal inoculation

Possibly sexually transmitted

53

Epidemiology

Worldwide

Except New Zealand

Reservoirs

Domestic animals

Sheep, cattle, goats

Dogs, cats

Birds

Reptiles

Wildlife

54

Epidemiology

Occupational and environmental hazards

Farmers, producers

Veterinarians and technicians

Meat processors, abattoir

Laboratory workers

55

Image courtesy of CDC

Human Disease

Incubation: 2-5 weeks

One organism may cause disease

Humans are dead-end hosts

Usually show clinical signs of illness

Disease

Asymptomatic (50%)

Acute

Chronic

57

Acute Infection

Flu-like, self limiting

Atypical pneumonia (30-50%)

Non-productive cough, chest pain

Acute respiratory distress possible

Hepatitis

Skin rash (10%)

Other signs (< 1%)

Myocarditis, pericarditis, meningoencephalitis

Death: 1-2%

58

Chronic Disease

1-5% of those infected

Prior heart disease, pregnant women, immunocompromised

Endocarditis

Other

Osteomyelitis

Granulomatous hepatitis

Cirrhosis

50% relapse rate after antibiotic therapy

59

Diagnosis

Serology (rise in titer)

IFA, CF, ELISA, microagglutination

DNA detection methods

PCR

Isolation of organism

Risk to laboratory personnel

Rarely done

60

Treatment

Treatment

Doxycycline

Chronic disease – long course

2-3 years of medication

Immunity

Long lasting (possibly lifelong)

61

Q Fever as a Biological Weapon

Accessibility

Low infectious dose

Stable in the environment

Aerosol transmission

WHO estimate

5 kg agent released on 5 million persons

125,000 ill - 150 deaths

Could travel downwind for over 20 km

62

Psittacosis

Avian Chlamydiosis

Parrot Fever

Ornithosis

63

Chlamydia psittaci

Obligate intracellular bacteria

Elementary body

Infectious

Survive for months in environment

Reticulate body

Non-infectious

Image courtesy of CDC PHIL

64

New Taxonomic Classification

Genus Chlamydia

C. trachomatis

C. muridarum

C. suis

Genus Chlamydophila

C. abortus

C. felis

C. pecorum

C. pneumoniae

C. caviae

C. psittaci

65

The Organism

Resistant to drying

Remains infectious for months

Remains viable on surfaces for 2-3 weeks

Survives in turkey carcass for >1 yr.

66

History

1879

First recognized human outbreak

7 people in contact with sick parrots

1929-1930

750 human cases

20% mortality

Large scale importation of infected birds from Argentina

1935

Wild psittacines in Australia

67

Epidemiology

Occurs worldwide

50-100 confirmed cases per year in U.S.

1-2 deaths

True incidence unknown

Nationally reportable in humans

Pet store employees, bird owners, poultry processing plant workers

68

Epidemiology

1988-2002

923 cases in U.S.

Many cases unreported or misdiagnosed

1980’s

70% of cases with known source due to exposure to caged birds

69

Psittacosis in U.S.: 1972-2002

Year

Reported Cases

250

225

200

175

150

125

100

75

50

25

0

1972 1977 1982 1987 1992 1997 2002

MMWR

Image courtesy of CDC

70

Populations at Risk

Lab workers

Veterinarians

Avian quarantine workers

Zoo workers

Farmers

Pregnant women

Bird fanciers (pigeon fanciers too)

Bird owners

Pet shop employees

Poultry slaughter and processing workers

Wildlife rehab workers

71

Transmission to Humans

Inhalation

Dried infective droppings

Secretions or dust from feathers

Mouth-to-beak

Direct contact

Handling plumage or tissues of infected birds

Person-to-person transmission

Not proven

Venereal transmission reported

72

Human Disease: Psittacosis

Incubation period: 1-4 weeks

Range

Inapparent infection

Systemic infection with pneumonia

Pneumonia 30-60 years of age

Common signs – abrupt onset

Fever, chills, headache, malaise, myalgia, sore throat, cough, dyspnea, splenomegaly, rash

73

Clinical Signs

May also see

Myocarditis, endocarditis

Arthritis, lethargy, hepatitis, epistaxis

Placentitis, fetal death

Encephalitis, jaundice, respiratory failure

Thrombocytopenia, coma, arthralgia

74

Diagnosis

Confirmed case

Clinical signs + laboratory results

Culture

4-fold rise in titer

IgM detected by MIF

Probable case

Linked epidemiologically to confirmed case of Psittacosis

Single titer 1:32

75

Differential Diagnosis

Coxiella burnetii (Q fever)

Legionella

Chlamydia pneumoniae

Mycoplasma pneumoniae

Influenza

Tularemia

76

Treatment and Prognosis

With treatment

1-5% case-fatality rate

Tetracyclines are drug of choice

Remission of symptoms

Usually in 48-72 hours

Relapse possible

Without treatment

May resolve in few weeks-months

10-40% case-fatality rate

77

Avian Species Affected

Isolated from over 100 avian species

Psittacines

Especially cockatiels and parakeets

Egrets, gulls, ratites

Pigeons, doves, mynah birds, sparrows

Turkeys, ducks

Rarely chickens

78

Diagnosis

Diagnosis difficult

Case definitions

Confirmed, probable, suspect

Single test may not be adequate

Combination testing recommended

Proper sample collection techniques critical for accurate results

Consult an experienced avian veterinarian

79

Psittacosis: The Bioweapon

Easily obtained

Aerosolized

Stable in the environment

80

Viral Encephalitis

Image courtesy of CDC PHIL

81

Human Clinical Signs

Most cases are asymptomatic

Flu-like illness in some

Sudden fever, headache, myalgia, malaise, prostration

Small proportion develop encephalitis

Permanent neurological damage

Death

82

Human Treatment

Manage symptoms

Reduce fever

Maintain hydration and electrolytes

Maintain blood oxygen levels

Anticonvulsants

Osmotic diuretics for intracranial pressure

Physical therapy

No effective anti-virals available

83

Human Risks and Outcomes

St. Louis Encephalitis (SLE)

Most common

Elderly most at risk

Case fatality rate: 5-15%

La Crosse Encephalitis (LAC)

Children <16 years most at risk

Human fatalities less than 1%

84

Human Risks and Outcomes

Eastern Equine Encephalitis (EEE)

Elderly most at risk

Case fatality rate: 33%

Western Equine Encephalitis (WEE)

Children younger than 1 year most at risk

Case fatality rate approximately 3%

Venezuelan Equine Encephalitis (VEE)

Children most often affected

Fatalities are rare

85

Animal Risks and Outcomes

Horse - Case-fatality rate

EEE ~ 90%

VEE ~ 40-80%

WEE ~ 20-50%

Vaccine available in the U.S.

Trivalent formalin-inactivated

SLE, LAC do not cause disease in horses or other non-human mammals

86

Venezuelan Equine Encephalitis

Peste loca

Image courtesy of CDC PHIL

87

VEE Viral Strains

Epizootic/Epidemic

I-A, I-B and I-C

Disease in humans and horses

Transmission by many mosquito species

Natural reservoir unknown

Horses and donkeys act as amplifiers

Enzootic/Endemic

Disease in humans

Transmission mainly by Culex (Melanoconion) species

Natural reservoir is rodents living in swamps and forests

88

VEE History

Western Hemisphere disease

Primarily Central and South America

1938: Isolated from a horse brain

1962-1964

Outbreak in Venezuela

23,000 human cases

1967

Outbreak in Colombia

220,000 human cases

Over 67,000 horse deaths

89

VEE History

1969-1971

Largest recorded outbreak in Guatemala

Area from Costa Rica to Rio Grande Valley in Texas

Thousands of human encephalitis cases

Over 100,000 horses died

Small outbreaks occur occasionally

1995

Venezuela and Colombia

Over 90,000 human cases

90

VEE Epidemiology

1971

Only U.S. outbreak - in Texas

Enzootic variant Everglades virus in south Florida

2-3 human cases, no horse disease

Infection in humans less severe than EEE or WEE

Fatalities rare, less than 1%

91

Human VEE

Initial signs

Last 24-48 hours

Fever, malaise, dizziness, chills, headaches, anorexia, severe myalgia, arthralgia, nausea, vomiting

Lethargy and anorexia can last 2-3 weeks

4-15% of cases become neurological

Mortality rates less than 1%

Most often in children with encephalitis

92

Human VEE

In utero death

Possible in pregnant women who contract the disease

Diagnosis

Paired sera with rising titer

ELISA IgG or IgM

Treatment: Supportive care

No vaccine available

Prognosis

Variable, often chronic fatigue and headaches

93

Animal VEE

Incubation period: 1-5 days

Horses most susceptible

Fever, anorexia, depression, flaccid lips, droopy eyelids and ears, incoordination and blindness

Death 5-14 days after clinical onset

Case-fatality rate: 38-83%

In utero transmission results in abortion, stillbirth

94

Animal VEE

Diagnosis

Paired sera with rising titer

ELISA IgG or IgM

Treatment: Supportive care

Vaccine available for horses

Trivalent, formalin inactivated

WEE, EEE, VEE combination

Days 0 and 30

Annual or biannual booster

95

VEE as a Biological Weapon

Aerosolized VEE

Human and equine disease occur simultaneously

Flu-like symptoms in humans

Possible neurological signs in horses

Large number of cases in a given geographic area

96

VEE as a Biological Weapon

50 kg virulent VEE particles

Aerosolized over city of 5 million people

150,000 people exposed

30,000 people ill

300 deaths

97

Ricin

Image courtesy of Lynne Railsback

98

Toxin

Castor plant - Ricinus communis

From processing waste

Castor beans for oil

Very stable

In several forms

Powder, mist, pellet, dissolved

in water or weak acid

Irreversibly blocks protein synthesis

Potential medical uses

99

History of Ricin

World War I

Considered for use as weapon by US

1978: London

Assassination of Bulgarian exile, Georgi Markov

1991: Minnesota

Patriot’s Council plot to kill US Marshal

100

History of Ricin (continued)

Iran-Iraq war

Reports of ricin use

Found in Al Qaeda caves in Afghanistan

2003

Ricin found in London apartment

2004

Toxin found in Senator’s office

Found in letter in South Carolina; source unknown

101

Transmission

Three routes

Inhalation

Ingestion

Injection

Person-to-person transmission does not occur

102

Signs and Symptoms

Inhalation

Incubation less than 8 hours

Ingestion

Incubation few hours to few days

Injection

Incubation immediate to hours

103

Clinical Symptoms

Inhalation

Cough, weakness, fever, nausea, muscle aches, chest pain and cyanosis

Pulmonary edema, 18-24 hours after inhalation

Severe respiratory distress

Death from hypoxemia, 36-72 hours

104

Clinical Symptoms

Ingestion

Least toxic form

Less toxic if castor beans swallowed whole

Severe GI symptoms, 1-2 hours

Rapid heartbeat

Internal bleeding

Vascular collapse

Death occurs in 3 days or more

105

Clinical Symptoms

Injection

Local pain and necrosis at site of injection

Systemic signs similar to those of ingestion

106

Diagnosis

Based on clinical symptoms

ELISA

Serum or respiratory secretions

Immunohistochemistry

Tissues

Serology for retrospective diagnosis

Ricin is very immunogenic

107

Treatment

No treatment, vaccine or antisera currently available

Supportive care

Dependent on route of exposure

Ventilator

Gastric lavage or cathartics

108

Ricin as a Biological Weapon

Extreme ease of production

Widely available

Relatively high toxicity

Currently no treatment

Supportive care only

109

Discussion Questions

Describe the life cycle of an arbovirus? Which of the viral Encephalitides has been exploited in former BW programs?

What is it about ricin that causes it to be used in so many recent biocrimes?

What are the attributes of Category B agents? Apply each of the criteria to the diseases discussed in Chapter 4.

In what ways are Brucella normally transmitted to humans?

In what ways would an intentional outbreak of Q fever overwhelm the medical and public health communities?

Chapter 4 Summary

Category B contains the agents of great concern

Be certain you know the criteria!

Know why each agent has been placed within the category – apply the criteria

Realize the potential that each agent has to confuse healthcare providers and create chaos

Content

Critical Thinking

Content

Discussion Questions

image1.png

image2.gif

image3.jpeg

image4.jpeg

image5.png

image6.jpeg

image7.jpeg

image8.jpeg

image9.png

image10.jpeg

image11.png

image12.jpeg

image13.jpeg

image14.jpeg